After grabbing 0.19 million shares, the institutional investor is now in possession of 0.19 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.43% having worth around $42864.0. Moreover, Baader Bank AG increased its share by 42050.0 to have a control over 42050.0 shares. And Gesalcalá SA SGIIC raised its holdings to 8048.0 shares by acquiring 26018.0 shares or 0.20% of the stake.
ReShape Lifesciences Inc. (RSLS) concluded trading on 12/28/23 at a closing price of $0.26, with 3.7 million shares of worth about $0.96 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.74% during that period and on Thursday the price saw a loss of about -4.59%. Currently the company’s common shares owned by public are about 13.14M shares, out of which, 12.97M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 14 times over the past 12 months. They bought 17,702 shares in 1 of the transactions. In 13 selling transactions, insiders dumped 1,262 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Alcala Multigestion FI – Garp are the top 3 mutual funds which are holding stakes in ReShape Lifesciences Inc. Vanguard Extended Market Index Fu is currently holding 49874.0 shares of worth totaling $11371.0. The company recently came buying 0.0 shares which brought its stake up to 0.38% of the company’s outstanding shares. Alcala Multigestion FI – Garp, after buying 12997.0 shares, have now control over 0.10% of the stake in the company. It holds 4024.0 shares of worth $2963.0.
ReShape Lifesciences Inc. (NASDAQ: RSLS) started trading at $0.28, above $0.01 from concluding price of the previous day. Stock saw a price change of -16.47% in past 5 days and over the past one month there was a price change of 24.87%. Year-to-date (YTD), RSLS shares are showing a performance of -96.21% which decreased to -95.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.19 but also hit the highest price of $22.40 during that period. The average intraday trading volume for ReShape Lifesciences Inc. shares is 8.02 million. The stock is currently trading -8.17% below its 20-day simple moving average (SMA20), while that difference is up 0.32% for SMA50 and it goes to -81.61% lower than SMA200.
Armistice Capital LLC acquired 0.19 million shares of ReShape Lifesciences Inc. having value of about $42864.0. ReShape Lifesciences Inc. (NASDAQ: RSLS) currently have 13.14M outstanding shares and institutions hold larger chunk of about 3.27% of that. Holding of mutual funds in the company is about 0.72% while other institutional holders and individual stake holders have control over 2.55% and 0.17% of the stake respectively.
The stock has a current market capitalization of $3.36M and its 3Y-monthly beta is at 0.22. It has posted earnings per share of -$39.12 in the same period. It has Quick Ratio of 0.94 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RSLS, volatility over the week remained 11.39% while standing at 18.02% over the month.
Analysts are in expectations that ReShape Lifesciences Inc. (RSLS) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.16 and it is -$0.45 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.18 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$8.59 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 96.47% while it is estimated to increase by 88.28% in next year.
Analysts at 1 brokerage firms have issued recommendations for the ReShape Lifesciences Inc. (RSLS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
